Disclosure – Non-Independent Marketing Communication
This is a non-independent marketing communication commissioned by International Biotechnology Trust. The report has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibition on the dealing ahead of the dissemination of investment research.
Not many investors would turn down capital growth, a stable yield, and diversification from one of the most exciting sectors in the marketplace. This is exactly what International Biotechnology Trust (IBT) and its Fund Manager, SV Health Managers LLP have provided the trust’s investors and why it is attracting a new and growing investor base.
Since the mid ‘90s, the biotechnology sector has boasted a compound annual growth rate of around 15% . IBT’s lead manager Carl Harald Janson aims to give investors in IBT exposure to that level of growth, as well as any outperformance the investment team can achieve with active management. Part of that growth is then paid to investors in the form of a dividend of 4% of its year-end NAV, paid from capital reserves and split over two semi-annual tranches.
Kepler Trust Intelligence provides research and information for professional and private investors. In order to ensure that we provide you with the right kind of content, and to ensure that the content we provide is compliant, you need to tell us what type of investor you are.Continue